Lanean...
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Libertas Academica
2012
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3327515/ https://ncbi.nlm.nih.gov/pubmed/22518088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S6460 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|